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Recent advances in high-throughput technologies have led to the emergence of systems biology as a holistic
science to achieve more precise modeling of complex diseases. Many predict the emergence of personalized
medicine in the near future. We are, however, moving from two-tiered health systems to a two-tiered personalized
medicine. Omics facilities are restricted to affluent regions, and personalized medicine is likely to widen the
growing gap in health systems between high and low-income countries. This is mirrored by an increasing lag
between our ability to generate and analyze big data. Several bottlenecks slow-down the transition from
conventional to personalized medicine: generation of cost-effective high-throughput data; hybrid education and
multidisciplinary teams; data storage and processing; data integration and interpretation; and individual and global
economic relevance. This review provides an update of important developments in the analysis of big data and
forward strategies to accelerate the global transition to personalized medicine.
Keywords: Big data, Omics, Personalized medicine, High-throughput technologies, Cloud computing, Integrative
methods, High-dimensionalityIntroduction
Access to large omics (genomics, transcriptomics, proteo-
mics, epigenomic, metagenomics, metabolomics, nutrio-
mics, etc.) data has revolutionized biology and has led to
the emergence of systems biology for a better understand-
ing of biological mechanisms. Systems biology aims to
model complex biological interactions by integrating in-
formation from interdisciplinary fields in a holistic man-
ner (holism instead of the more traditional reductionism).
In contrast to treating a mixture of factors as single
entities leading to an endpoint, systems biology relies on
experimental and computational approaches in order to
provide mechanistic insights to an endpoint [1]. Trad-
itional observational epidemiology or biology alone are
not sufficient to fully elucidate multifaceted heterogeneous
disorders and this directly limits all prevention and treat-
ment pursuits for such diseases [2, 3]. It is widely recog-
nized that multiple dimensions must be considered
simultaneously to gain understanding of biological sys-
tems [4]. Systems approaches are driving the leading-edge* Correspondence: meyred@mcmaster.ca
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networks for normal and abnormal phenotypes are
thought to allow for the proactive maintenance of wellness
specific to the individual, that is predictive, preventive,
personalized, and participatory medicine (P4, or more
generally speaking, personalized medicine) [1].
Many predict the emergence of personalized medicine
in the near future, but it is not likely to come about as
quickly as the scientific community and the media may
think [7]. In parallel to an escalating two-tiered health
system at the global level, a similar two-tiered phenomenon
is observed with regard to our ability to generate and
analyze omics data that may delay even further the transi-
tion to personalized medicine. The generation and manage-
ment (storage, and computational resources) of omics data
remain expensive despite technological progress. This im-
plies that personalized medicine could be restricted to the
wealthier countries [8]. This is mirrored by a growing gap
in our abilities to generate and interpret omics data. The
bottleneck in omics approaches is becoming less and less
about data generation and more and more about data man-
agement, integration, analysis, and interpretation [9]. There
is an urgent need to bridge the gap between advances in
high-throughput technologies and our ability to manage,ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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review addresses the growing gaps in socioeconomic and
scientific progress toward personalized medicine.
Review
The rich get richer and the poor get poorer
The developing world is home to 84 % of the world’s
population, yet accounts for only 12 % of the global
spending on health [13]. There is a large disparity be-
tween the distribution of people and global health ex-
penditures across geographical regions (Fig. 1). While
public financing of health from domestic sources has in-
creased globally by 100 % from 1995 to 2006, a majority
of low and middle-income countries experienced a re-
duction of funding during the same time [14]. Several
life-threating but easily preventable or treatable diseases
are still prevalent in developing countries (e.g. malaria).
Personalized medicine will further increase these dispar-
ities and many low and middle-income countries may
miss the train of personalized medicine [15–17], unless
the international community devotes important efforts
towards strengthening health systems of the most disad-
vantaged nations.
Systems medicine, the application of systems biology
to human diseases [18], requires investments in infra-
structures with cutting-edge omics facilities and analyt-
ical tools, advanced digital technologies (high computing
performance and storage resources), and highly-qualified
multi-disciplinary teams (clinicians, epidemiologists, biol-
ogists, computer scientists, statisticians and mathemati-
cians) in addition to investments in security and privacy.
On the bright side, technology is evolving quickly and
new developments are producing data more efficiently. A
few examples include the development of high-through-
put next generation sequencing and microarrays inFig. 1 Distributions of populations and global health expenditure accordingenomics and transcriptomics, mass spectrometry-based
flow cytometer in proteomics, real-time medical imaging,
and more recently, lab-on-a-chip technologies [19]. Some
predict that a technological plateau may be reached for
different reasons (reliability, cost-effectiveness), but these
projections are not validated by historical trends in science
as novel technological developments can always occur
[20]. However, there is a consensus that most of the cost
in omics studies will come from data analysis rather than
data generation [9].
The economic value of omics networks as personalized
tests for future disease onset or response to specific
treatments / interventions remains largely unknown. A
recent study by Philips et al. reflects this issue and high-
lights a lag between clinical and economical value
assessment of personalized medical tests in current re-
search [21]. Very few studies have incorporated an eco-
nomic aspect in the evaluation of personalized tests.
These tests range from those available in clinical use or
in advanced stage of development, genetic tests with
Food and Drug Administration labels, tests with demon-
strated clinical utility, and tests examining conditions
with high mortality or high health-associated expendi-
tures. Economic evaluations of personalized tests are
needed to guide investments and policy decisions. They
are an important pre-requisite to hasten the transition
to personalized medicine. In addition, those few person-
alized tests that included economic information were
found to be relatively cost-effective, but only a minority
of them were cost-saving, suggesting that better health is
not necessarily associated with lower expenditures [21].
In summary, the costs associated with personalized
medicine transition remain unclear, but personalized
medicine may further widen the economic inequality in
health systems between high and low-income countries.g to WHO 2012
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and highlights the need for a broader translation-oriented
focus across the globe [22].
Several ideas for stimulating sustainable innovations in
developing nations include micro-grants as proposed by
Ozdemir V. et al. [23]. Although $1,000 micro-grants
are relatively small, they far exceed the annual income of
individuals below the poverty line of $1.25/day as de-
fined by the World Bank. Recipients of these grants may
go a long way in connecting and co-producing know-
ledge based innovations to broaden translational efforts.
Type 1 micro-grants which are awarded through funding
agencies may support small labs and local scholars to
connect personalized medicine with new models of dis-
covery and translation [23]. Type 2 micro-grants funded
by science observatories and/or citizens through crowd-
funding mechanisms may facilitate developments of glo-
bal health diplomacy to share novel innovations (i.e.
therapeutics, diagnostics) in areas with similar burdens
[23]. There is an overall need to support local scholars
in promoting knowledge and innovation within low and
middle-income countries [24]. This includes for ex-
ample, the case of advocating for treatment of persons
with Human Immunodeficiency Virus (HIV) infections
where their peers may not recognize their illness as an
endemic that affects society [24]. One successful ex-
ample of personalized medicine for HIV patients in low
and middle-income countries include personal text mes-
sages for improving adherence to antiretroviral therapy
in Kenya and Cameroon [25].
Interdisciplinary programs for global translational sci-
ence such as the Science Peace Corps are another prom-
ising catalyzing agent for research and developments in
low and middle-income countries (http://www.peace-
corps.gov/) [22]. The present Peace Corps program en-
tails volunteer work (6 weeks minimum and up to
2 years) in various regions across the globe to serve as a
steady flux of knowledge for translational research. Jun-
ior or senior scientists may cover topics from life sci-
ences, medicine, surgery, and psychiatry. This program
is bi-directional as it serves both the rich and poor to
elucidate the concept of “health” and integrate personal-
ized medicine within various environments. Lagging de-
velopments in low and middle-income countries are in
fact open opportunities with rewards for intellectual
individuals given the simple fact that it is where the
majority of the human populations reside.
The “tragedy of the commons” is a conceptual economic
problem where the benefits of common and open re-
sources are jeopardized by individuals’ self-interest to
optimize personal gains [26]. The 2009 Economics Nobel
Laureate, Elinor Ostrom, has shown that this issue is not
actually common among humans since individuals work
through establishing trust, and tend to find solutions tocommon problems themselves [27]. Societies do systemat-
ically develop complex sustainable regulations to collect-
ively benefit each other where assurance is a critical factor
for cooperation [28]. There is a need to understand ins-
titutional diversity if humans are to act collectively to
benefit each other. Diverse applications of personalized
medicine can be envisioned to cope with the diversity of
the world by allowing multi-tier personalized health care
systems at multiple scales and avoiding a single top-tier
health care system that may instead compromise resource
management. This also brings about the need for nested
regulation systems for both science and ethics (i.e. ethics-
of-ethics) as the assurance factor for cooperation [29, 30].
Transparency and accountability need to be imposed on
all scientists, practitioners, ethicists, sociologists, and pol-
icymakers. No one should be above the fray for account-
ability if a sustainable transition towards personalized
medicine is to occur.
Omics data: the shifting bottlenecks
In parallel to the gap in health systems between rich and
poor countries that personalized medicine may widen,
an increasing lag has been observed in our ability to
generate versus integrate and interpret omics data these
last ten years [9]. New technologies and knowledge
emerging from the Human Genome Project, fueled by
biotechnology companies, led to the omics revolution in
the beginning of the 21th century [31]. Using high-
throughput technologies, we are now able to perform an
exhaustive number of measurements over a short period
of time giving access to individuals’ DNA (genomics),
transcribed RNA from genes over time (transcriptomics),
DNA methylation and protein profiles of specific tissues
and cells (epigenomics and proteomics), metabolites
(metabolomics), among other types of omics data [32].
Even histopathological and radiological images which
are traditionally evaluated and scored by trained experts
are now subjected to computational quantifications (i.e.
imaging informatics) [10–12, 33]. Business models based
on returns on investments have driven ongoing techno-
logical developments to accelerate the generation of
omics data at increased affordability in comparison with
existing technologies. As a consequence, omics plat-
forms and individual omics profiles are expected to be-
come fairly affordable and data generation is no more a
bottleneck for most laboratories, at least in the middle
and high-income countries [34].
Initially, there were great expectations for omics data
to provide clues on the mechanisms underlying disease
initiation and progression as well as new strategies for
disease prediction, prevention and treatment [1]. The
idea was to translate omics profiles into subject-specific
care based on their disease networks (Fig. 2). However, our
ability to decipher molecular mechanisms that regulate
Fig. 2 A basic framework of personalized medicine. The integration of omics profiles permit accurate modeling of complex diseases and opens
windows of opportunities for innovative clinical applications to subsequently benefit the patient
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access to omics profiles. Biological processes are very com-
plex, and this coupled with the noisy nature of experimen-
tal data (e.g. cellular heterogeneity) and the limitations of
statistical analyses (e.g. false positive associations) poses
many challenges to detecting interactions between “net-
works” and “networks of networks”. As an illustration, only
a minority of the genetic variants predisposing to type 2
diabetes have been identified so far, despite large-scale
studies involving up to 150,000 subjects [1, 35]. It becomes
more and more obvious that the bottleneck in laboratories
has shifted from data generation to data management and
interpretation [36].
Personalized medicine needs hybrid education
Although solutions for the challenges of big data already
exist and are adopted by companies such as Google, Apple,
Amazon, and Facebook to tackle the fairly homogenous
big data (i.e. user data) [37], the heterogeneous nature of
omics data presents a new challenge that requires sufficient
understanding of the underlying biological concepts and
analysis algorithms to carry out data integration and inter-
pretation [38]. It is important for the working scientist to
understand 1) the underlying problem, 2) the methods of
data analysis, and 3) the advantages, and disadvantages of
different computational platforms to carry out explorations
and draw inference. Expertise in biology provides a founda-
tion to contextualize causal effects and guide identification
and interpretation of interaction signals from noise. There
is also no uniformly most powerful method to analyzeomics data and the use of various approaches to infer
biological interactions requires modeling expertise [39].
Otherwise, research quality is sacrificed to avoid the logis-
tical challenges of modeling in exchange for the use of
more straightforward approaches [40]. Lastly, computer
programing skills are necessary to navigate explorations
and analyze omics data accordingly. There is a need for re-
liable and maintainable computer codes through best prac-
tices for scientific computing [41]. Approximately 90 % of
scientists are self-taught in developing software and
one may lack basic practices such as task automation,
code review, unit testing, version control and issue
tracking [42, 43]. Barriers between disciplines still exist
between informaticians, mathematicians, statisticians,
biologists, and clinicians due to a too divergent scien-
tific background. Cutting-edge science is integrative by
essence and innovative strategies in universities to edu-
cate and train future researchers at the interface of
traditionally partitioned disciplines is urgently needed
for the transition to personalized medicine. Johns
Hopkins University is leading this evolution by chan-
ging the teaching plans and establishing new programs
in the school of medicine that integrate the notion of
personalized medicine [44]. Although increased know-
ledge at the population level is a key factor in develop-
ment of modern societies, there is an upper limit to the
wealth of knowledge and expertise a single individual
can hold [45]. This is the reason why, in addition to
multidisciplinary individual training, initiatives by uni-
versities, research funding agencies, and governments
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entific backgrounds on interface topics related to sys-
tems biology and personalized medicine. The recent
shift by the Canadian Institutes of Health Research from
distinct discipline (e.g. genetics) to multidisciplinary ex-
pert panels in funding biomedical research is a step in the
right direction. The creation of interdisciplinary research
institutes, such as the Steno Diabetes Center in Denmark
that combine clinical, educational and multifaceted re-
search activities to lead translational research in diabetes
care and prevention, is another sensible initiative that
could prefigure what may become personalized medicine
institutes in the future.
Management and processing of omics data
Major investments need to be made in bioinformatics,
biomathematics, and biostatistics by the scientific commu-
nity to accelerate the transition to personalized medicine.
Classic research laboratories do not possess sufficient stor-
age and computational resources for processing omics
data. Laboratory-hosted servers require investments in in-
formatics support for configuring and using software.
Such servers are not only expensive to setup and maintain,
but do not meet the dynamic requirements of different
workflows for processing omics data, leading to either ex-
travagant or sub-optimal servers. One promising technol-
ogy to close the gap between generation and handling of
omics data is cloud computing [46, 47]. It is an adaptive
storage and computing service that exploits the full poten-
tial of multiple computers together as a virtual resource
via the Internet [48]. Examples include the EasyGenomics
cloud in Beijing Genomics Institute (BGI), and “Embassy”
clouds as part of ELIXIR project in collaboration with
multiple European countries (UK, Sweden, Switzerland,
Czech Republic, Estonia, Norway, the Netherlands, and
Denmark) [49]. The focus is currently placed on develop-
ing cloud-based toolkits and workflow platforms for high-
throughput processing and analysis of omics data [50, 51,
49, 52]. More recently, Graphics Processing Units (GPUs)
have been proposed for general-purpose computing in a
cloud environment [53]. GPUs provide faster computa-
tions as accelerators by one or two orders of magnitudes
compared to general Central Processing Units (CPUs) and
have been exploited to cope with exponentially growing
data [54–56]. MUMmerGPU for example, processes quer-
ies in parallel on a graphics card, achieves more than a 10-
fold speedup over a CPU version of the sequence alignment
kernel, and outperforms the CPU version of MUMmer by
3.5-fold in total application time when aligning reads [57].
However, a significant amount of work will be required
for developing parallelization algorithms considering the
heterogeneous framework of omics data that present
challenges in communications and synchronizations [37].
There are tradeoffs between computational cost (floating-point operations), synchronization, and communications to
consider while developing parallelization algorithms [58].
Moreover, developing error-free and secure applications is
a challenging and labor-intensive, yet critically important
task. Examples of programming errors and studies outlining
wrongly mapped SNPs in commercial SNP chips have been
reported in literature [59–61]. There is a need to validate
the reliability of research platforms before considering the
clinical utility of omics data. For instance, ToolShed, a fea-
ture of the Galaxy project that draws in software developers
worldwide to upload and validate software tools, aims to
enhance the reliability of bioinformatics tools. Novel tools
and workflows with demonstrated usefulness and ins-
tructions are publically available (http://toolshed.g2.bx.p-
su.edu/) [62]. Both storage and computing platform such
as Bioimbus [63], Bioconductor [64], CytoScape [65], are
made available by scientists to exchange algorithms and
data. There are many questions and methodologies that
researchers may wish to consider, and this continuously
drives on novel bioinformatics tools. Ultimately, light-
weight programing environments and supporting pro-
grams with diverse cloud-based utilities are essential to
enable those without or with limited programing skills to
investigate biological networks [66]. Figure 3 illustrates a
cloud-based framework that may help to implement per-
sonalized medicine. Much more programing efforts are
still needed for the integration and interpretation of omics
data in the transition to personalized medicine. Potential
downstream applications are not always apparent when
data are generated, promoting sophisticated flexible pro-
grams that may be regularly updated [67].
Integrative methods of omics data
Lastly, the depiction of biological systems through the
integration of omics data requires appropriate mathem-
atical and statistical methodologies to infer and describe
causal links between different subcomponents [40]. The
integration of omics data is both a challenge and an
opportunity in biostatistics and biomathematics that is
an increasing reality with the decreasing costs of omics
profiles. Aside from the computational complexity of
analyzing thousands of measurements, the extraction of
correlations as true and meaningful biological interac-
tions is not trivial. Biological systems include non-linear
interactions and joint effects of multiple factors that
make it difficult to distinguish signals from random
errors. Caspase-8 for example, has opposing biological
functions as it promotes cell death by triggering the extrin-
sic pathway of apoptosis, while having beneficial effects on
cell survival through embryonic development, T-lympho-
cyte activation, and resistance to necrosis induced by tumor
necrosis factor-α (TNF-α) [68]. Genes may carry out differ-
ent functions in different cell types / tissues, which adds to
the already substantial inter-individual variability. Biological
Fig. 3 An interdisciplinary cloud-based model to implement personalized medicine. The consecutive knowledge and service swapping between
modeling and software experts in research and development units is essential for the management, integration, and analysis of omics data.
Thorough software and model development will derive updates upon knowledge bases for complex diseases, in addition to clinical utilities,
commercial applications, privacy and access control, user-friendly interfaces, and advanced software for fast computations within the cloud. This
translates into personalized medicine via personal clouds that upload wellness indices into personal devices, electronic databases for health
professionals, and innovative medical devices
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mation within high-dimensional data [69]. Both computa-
tional and experimental methodologies are needed to fully
elucidate biological networks. However, in contrast to ex-
perimental assays, computational models rely on biologic-
ally driven variables and have inherent pitfalls of omics data.
Coping with to the curse of dimensionality
High-dimensionality is one of the main challenges that
biostatisticians and biomathematicians face when deci-
phering omics data. It is the issue of “large p, small n”,
where the number of measurements, p, is far greater
than the number of independent samples, n [69, 33].
The analysis of thousands of measurements often leads
to results with poor biological interpretability and
plausibility. The reliability of models decreases with each
added dimension (i.e. increased model complexity) for a
fixed sample size (i.e. bias-variance dilemma, see Fig. 4)
[69]. All estimate instability, model overfitting, local
convergence, and large standard errors compromise the
prediction advantage provided by multiple measures. Abetter understanding of these inherent caveats comes
from the key concept behind statistical inference that is
the distribution of repeated identical experiments. This
distribution can be characterized by parameters such as
the mean, and variance that quantify the average value
(i.e. effect size), and degree of variability (i.e. biological
or experimental noise). These parameters are estimated
from observed data drawn from the true distribution
(i.e. a finite number of independent samples). The
reliability of estimates from a small sample size is low
where it is more likely to observe estimates that deviate
from the true distribution parameters. The chance of en-
countering such deviations also increases with the num-
ber of different measurements in a fixed sample. It is
difficult to reliably estimate many parameters, and cor-
rectly infer associations from multiple hypotheses tested
simultaneously. As a result, the analysis of both single
and integrative omics data is prone to high rates of
false-positives due to chance alone. This requires re-
searchers to adjust for multiple testing to control for
type 1 error rate using various methods based on the
Fig. 4 The bias-variance tradeoff with increasing model complexity
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and Young permutation), and the false-positive rate (e.g.
Benjamin and Hochberg) that are under strict assumptions
[70–75]. Another solution to overcome multiple testing is-
sues is to reduce dimensionality via sparse methods that
provide sparse linear combinations from a subset of rele-
vant variables (i.e. sparse canonical correlation analysis,
sparse principal components analysis, sparse regression)
[76, 77]. Both mixOmics and integrOmics are publically
available R packages for utilizing sparse methods on omics
data [77, 78]. There are several approaches to derive “opti-
mal” tuning parameters to dictate the number of relevant
variables to pursue [79, 80]. However, stochastic processes
to select “best” subsets of variables inferred from a given
sample population may not contain the best information on
another independent study, and certainly not at an individ-
ual level (i.e. selection-bias) [81, 82]. Reducing dimensional-
ity is problematic as key mechanistic information could be
lost. There is an overall tradeoff between false positive rates
and the benefit of identifying novel associations within bio-
logical process that align with that of bias and variance
(Fig. 4) [70].
The multi-level ontology analyses (MONA) is one ap-
proach that bypasses the high-dimensionality as de-
scribed by Sass et al. [83]. This method integrates
multiple omics information (DNA sequence, mRNA and
protein expressions, DNA methylation, and other regula-
tion factors) and copes with redundancies related to
multiple testing problems by approximating marginal
probabilities using the expectation propagation algo-
rithm [84]. The MONA approach allows for biological
insights to be incorporated into the defined network as
prior knowledge. This can address overfitting or uncer-
tainty issues though reducing the solutions space to
biological meaningful regions [85, 86]. This approach,
however, relies on predefined known biological networks(i.e. protein–protein interactions) or on the accuracy of
mechanistic models (i.e. network models). Another strat-
egy to analyze omics data involves integrating multiple
data types into one single data set that holds maximum
information. This reduces the complexity of omics data
to the analysis of a single high-dimensional data set. Co-
inertia analysis for example, has been used to integrate
both proteomic and gene expression data to visualize
and identify clusters of networks [87, 88]. It was initially
introduced by Culhane et al. to compare gene expres-
sion data provided by different platforms, but has been
further generalized to assess similarities between omic
data sets [89]. The basic principal is to apply within
and between principal component analysis, corres-
pondence analysis, or multiple correspondence analysis
while maximizing the sum of squares of covariances
between variables (i.e. maximizing co-inertia between
hyperspaces). The omicade4 package in R is available
for exploring omics data using multiple co-inertia
analysis [90]. Other similar, but conceptually different
approaches include generalized singular value decom-
position [91], and integrative bioclustering methods
[92, 93]. An integrative omics study by Tomescu
et al., have utilized all three approaches to characterize
networks within Plasmodium faclicparum at different
stages of life cycles [94]. Although the basic mathem-
atical assumptions are different, the overlap in their
results was considerable. The relative importance and
incremental value of individual omics data on one an-
other may also be considered when predicting specific
outcomes. For instance, Hamid et al. recently pro-
posed a weighted kernel Fisher discriminant analysis
that accounts for both quality and informativity of
each individual omics data to integrate [95]. Significant
improvements however, may not occur when data are
redundant (i.e. correlated) or of low quality.
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Another challenge for integrating omics data lies in
deriving meaningful interpretable correlations. For ex-
ample, direct correlation analyses between transcripto-
mics and proteomics profiles are not valid in eukaryotic
organisms. No high correlations between the two do-
mains were observed as reported by multiple studies,
and this was attributed to post-transcriptional and post-
translational regulations [96–99]. The advantage of inte-
grating transcriptomic and proteomic data may diminish
without accounting for regulation factors as the resulting
inflated variability may limit reliability and reproducibil-
ity of findings [100]. Many complex traits are tightly reg-
ulated and incorporating regulation factors may explain
a relevant portion of observed variations due to true
heterogeneity (i.e. true differences in effect sizes). Unlike
the impact of noise on estimate precision which could
be minimized by increasing the sample size, true
heterogeneity may only be adjusted for during analysis
when possible or via standardizations that limit
generalizability. True heterogeneity poses a problem
given biological complexity in the pursuit of preciseFig. 5 Noise and true heterogeneity within complex systems. Source of no
heterogeneity however, is the result of true differences of effect sizes due to
and temporal associations; and 2) multi-factorial complexity. Increasing the
sizes, but true heterogeneity can only be adjusted during analysis when
generalizability of the conclusionseffect size estimations (Fig. 5). Hence, there is a need for
network analysis to account for protein-protein and pro-
tein-DNA interactions in the context of integrating tran-
scriptomics and proteomics data alone. An early study
by Hwang et al. utilized network models to identify pro-
tein-protein and DNA-protein interactions with experi-
mental verifications [101].
Bayesian networks are graphical models that involve
structure and parameter optimization steps to represent
probabilistic dependencies [102]. This modeling strategy
that elucidates biological networks has been utilized in
various studies [103, 104]. A seminal example includes
the use of dynamic Bayesian networks trained on chroma-
tin data to identify expressed and non-expressed DNA
segments in a myeloid leukemia cell line [105]. This was
done by integrating position of histone modifications, and
transcription factors’ binding sites at multiple intervals. It
is however, a computationally demanding approach that
requires advanced computing methods such as parallel
computing and acceleration via GPUs [106]. Network
models may serve as meaningful statistical results to be
integrated with the biological domain. It has the potentialise include measurement error and sampling variability. True
1) the dynamic biological nature which encompasses feedback loops
sample sizes is one solution to bypass noise and attain precise effect
possible and via standardizations and calibrations that limit
Fig. 6 Bottleneck toward personalized medicine. The collective challenges to make the transition from conventional to personalized medicine
include: i) generation of cost-effective high-throughput data; ii) hybrid education and multidisciplinary teams; iii) data storage and processing; iv)
data integration and interpretation; and v) individual and global economic relevance. Massive global investment in basic research may precede
global investment in public health for transformative medicine
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logical interactions to be experimentally and/or inde-
pendently verified through a follow-up validation set.
The ultimate goal is to continuously provide insight
into biological interactions to subsequently build upon.
Separate the wheat from the chaff
It is important to minimize sources of error with omics
data as it is challenging to distinguish between random
error and true interaction signals. Hence, it is necessary
to utilize statistical methods to account for sources of
error. For example, the quality of omics data may vary
between high-throughput platforms. Hu et al. have pro-
posed quality-adjusted effect size models that were used
to integrate multiple gene-expression microarray data
given heterogeneous microarray experimental standards
[107]. Omic studies are also prone to errors such as
sample swapping and improper data entry. New method-
ologies for assessing data quality include Multi-Omics
Data Matcher (MODMatcher) [108]. Moreover, complex
diseases are often evaluated using a single phenotype
that compromises statistical analysis by introducing er-
rors such as misclassifications, and/or lack of account-
ability for disease severity [109]. Modeling images for
example, requires multiple phenotypes to properly cap-
ture image features [110]. Joint modeling of multiple re-
sponses to accurately capture complex phenotypes hasbeen shown to increase power of discovery in genome-
wide association studies [111]. There are even novel net-
work methodologies to account for within-disease
heterogeneity [112, 113]. Network approaches in model-
ing complex diseases may provide a map of disease pro-
gression and play a major role in the proactive
maintenance of wellness [114]. All reproducibility and
validations of complex interaction signals are essential in
the pursuit of personalized medicine. This highlights the
growing need for metadata as the science of hows (i.e.
“data about data”) to help harmonize omics studies and
enable proper reproducibility of research results [115].
Examples of a metadata checklist and a metadata publi-
cation are available [116, 117]. Metadata may also serve
as open innovations for integrative sciences, and may
prove to be valuable for diversifying models of discovery
and translation in high, and more importantly, low
and middle-income countries. Altogether, validations on
multiple data sets are required as evidence of stability,
and that theoretically sound new methods outperform
existing ones [118]. Both descriptive and mechanistic
models for determining relevant biological networks re-
quire handling with care [119]. Software that integrate
and interpret omics data are currently developed by
competing companies in the private sector (e.g. Anaxo-
mics, LifeMap), which may rapidly advance the field in
the near future.
Alyass et al. BMC Medical Genomics  (2015) 8:33 Page 10 of 12Conclusion
This review aims to stimulate research initiatives in the
field of big data analysis and integration. Omics data
embody a large mixture of signals and errors, where our
current ability to identify novel associations comes at
the cost of tolerating larger error thresholds in the con-
text of big data. Major investments need to be made in
the fields of bioinformatics, biomathematics, and biostat-
istics to develop translational analyses of omics data and
make the best use of high-throughput technologies. New
generations of multi-talented scientists and multidiscip-
linary research teams are required to build accurate
complex disease models and permit effective personal-
ized prevention, diagnosis and treatment strategies. Our
ability to integrate and interoperate omics data is an im-
portant limiting factor in the transition to personalized
medicine. Overcoming these limitations may boost the
nation-wide implementation of omics facilities in clinical
settings (Fig. 6). The subsequent economies of scale may
in turn favor the access to personalized medicine to dis-
advantaged nations, repelling the growing shadow of
two-tiered personalized medicine.
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